Team:NMU China/Contribution
We found that the description of the part trastuzumab4D5-5 scFv-CAR (BBa_K3132022) designed by Qiliang Yang (iGEM19_SMMU-China) is wrong.
This part was described as a second-generation chimeric antigen receptor, whose single chain variable fragment（scFV） was derived from trastuzumab. However, their description "Therefore, this part can target EGFR." is incorrect.
We explained why this part can target HER2 but not EGFR:
This part contains an scFv derived from the famous antibody trastuzumab, which sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. It is specifically used for cancer that is HER2 receptor-positive. It may be used by itself or together with other chemotherapy medication. Trastuzumab is given by slow injection into a vein and injection just under the skin. Therefore, it can target HER2.
We added an illustration of the Trastuzumab Fab region (cyan) in combination with the HER2/neu (gold) PDB.
We added the sequence of this part.
